Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in VTRS — Viatris Inc

CIK 1423053 MIAMI, FL
Back to VTRS Full portfolio

Position in VTRS

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$7,975,872
-$45,971,651 QoQ
Shares Held
502,259
-87.4% QoQ
Ownership
0.044%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#140
of 1,020 holders
Holding Since
Dec 2020
23 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in VTRS Over Time

Shares Held

Position Value (USD)

Derivatives in VTRS

reported options exposure · as of Jun 30, 2026
CallValue
$10,496,680
CallShares
661,000
PutValue
$3,839,784
PutShares
241,800

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Jun 30, 2026

CITADEL ADVISORS LLC holds $1,255,121,114 across 64 Drug Manufacturers - Specialty & Generic names. VTRS ranks #14 (0.6% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ELAN
Elanco Animal Health Inc
 9,668,611 $237,944,516
2 ZTS
Zoetis Inc.
 3,188,263 $229,108,578
3 UTHR
UNITED THERAPEUTICS Corp
 304,692 $165,091,266
4 LNTH
Lantheus Holdings, Inc.
 1,376,480 $152,706,691
5 INDV
Indivior Pharmaceuticals, Inc.
 2,667,827 $109,460,941
6 ALKS
Alkermes plc.
 1,645,101 $86,203,291
7 SUPN
Supernus Pharmaceuticals, Inc.
 1,373,982 $63,903,902
8 HIMS
Hims & Hers Health, Inc.
 846,936 $29,363,271

All Filings in VTRS

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $7,975,872 502,259
2026-06-30 $10,496,680 661,000
2026-06-30 $3,839,784 241,800
2026-03-31 $3,357,235 248,500
2026-03-31 $14,867,755 1,100,500
2026-03-31 $53,947,523 3,993,155
2025-12-31 $6,476,490 520,200
2025-12-31 $102,554,172 8,237,283
2025-12-31 $2,664,300 214,000
2025-09-30 $103,616,241 10,466,287
2025-09-30 $4,132,260 417,400
2025-09-30 $6,276,600 634,000
2025-06-30 $6,710,895 751,500
2025-06-30 $1,752,959 196,300
2025-06-30 $66,344,291 7,429,372
2025-03-31 $6,790,316 779,600
2025-03-31 $14,150,266 1,624,600
2025-03-31 $53,584,276 6,152,041
2024-12-31 $1,370,745 110,100
2024-12-31 $123,962,271 9,956,809
2024-12-31 $8,741,145 702,100
2024-09-30 $5,587,893 481,300
2024-09-30 $2,853,738 245,800
2024-09-30 $49,028,553 4,222,959
2024-06-30 $1,871,634 176,071
2024-06-30 $5,301,181 498,700
2024-06-30 $2,354,545 221,500
2024-03-31 $5,076,888 425,200
2024-03-31 $5,801,646 485,900
2024-03-31 $1,700,745 142,441
2023-12-31 $3,604,224 332,800
2023-12-31 $2,960,922 273,400
2023-12-31 $1,856,998 171,468
2023-09-30 $3,512,132 356,200
2023-09-30 $3,206,432 325,196
2023-09-30 $2,574,446 261,100
2023-06-30 $13,450,894 1,347,785
2023-06-30 $2,116,758 212,100
2023-06-30 $4,308,366 431,700
2023-03-31 $2,088,502 217,100
2023-03-31 $55,165,745 5,734,485
2023-03-31 $5,723,900 595,000
2022-12-31 $7,537,102 677,188
2022-12-31 $86,128,614 7,738,420
2022-12-31 $3,412,458 306,600
2022-09-30 $2,691,979 315,960
2022-09-30 $5,789,305 679,496
2022-09-30 $93,024,656 10,918,387
2022-06-30 $7,528,935 719,096
2022-06-30 $57,021,399 5,446,170

Report a Problem

Category
Description
Email (optional, for follow-up)